The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy
Survival rates in the obinutuzumab/chlorambucil and rituximab/chlorambucil groups were 91% vs 84% at 2 years and 66% vs 57% at 5 years. There
To compare the safety of obinutuzumab by: 5. Comparing how well obinutuzumab versus rituximab in treating the disease. 6. Comparing the
This may explain why obinutuzumab improve PFS of CD20 NHL patients compared with rituximab. Although obinutuzumab-based therapy significantly prolonged PFS compared with rituximab-based therapy
More recently, the GALLIUM trial demonstrated the superiority of obinutuzumab vs rituximab [16, 17], and the RELEVANCE trial suggested that rituximab in combination with lenalidomide (R-Len) was
Comparing Obinutuzumab vs Rituximab ; Obinutuzumab has an average rating of 9.5 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20 primary
Obinutuzumab in combination with bendamustine for treating rituximab rituximab, often followed by maintenance therapy with rituximab. However
the two anti-CD20 monoclonal antibodies rituximab and obinutuzumab in untreated patients with follicular (44.6% vs. with bendamustine vs. less than 2% with
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are